GlassScriptPhysician profile
Matthew Pagano
NPI 1629464151
$3,392.33
in general payments reported to CMS, 2019-2025
35 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $445 · 2021: $63.49 · 2022: $14.76 · 2023: $22.14 · 2024: $1,447 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.46 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $361.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $261.19 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $255.00 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $246.68 | 2020-2025 | |
| Lilly USA, LLC | $147.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Intra-Sana Laboratories | $136.20 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Abbott Laboratories | $115.87 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $113.96 | 2024-2025 | Veozah |
| Eisai INC. | $107.03 | 2024 | |
| Bausch Health US, LLC | $98.13 | 2024-2025 | Aplenzin |
| Amgen INC. | $93.44 | 2020-2025 | Repatha, Otezla, Otezla |
| Corium, LLC | $78.53 | 2024 | Azstarys |
| Xeris Pharmaceuticals, INC. | $76.84 | 2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $73.57 | 2019-2025 | Austedo Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $71.79 | 2024-2025 | |
| Tolmar, INC. | $68.83 | 2024-2025 | Jatenzo |
| Axsome Therapeutics, INC. | $65.09 | 2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.06 | 2024-2025 | Jardiance |
| Mdd US Operations, LLC | $52.93 | 2020 | |
| Dexcom, INC. | $51.60 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $51.35 | 2024-2025 | Zoryve |
| Exact Sciences Corporation | $41.22 | 2025 | The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.98 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $29.31 | 2019 | |
| Inspire Medical Systems, INC. | $25.19 | 2024 | Inspire |
| Kerecis Limited | $22.14 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Allergan, INC. | $21.84 | 2020 | |
| Madrigal Pharmaceuticals | $21.77 | 2024 | Resmetirom |
| Gilead Sciences, INC. | $21.17 | 2019 | |
| Ardelyx, INC. | $19.93 | 2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $16.91 | 2025 | |
| Dynavax Technologies Corporation | $14.76 | 2022 | |
| Biodelivery Sciences International, INC. | $13.98 | 2020 | |
| Amarin Pharma, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pagano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.